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Abstract
Sortases are cysteine transpeptidases found primarily on the cell surface of Gram-positive
bacteria. Sortase-mediated ligations have become an attractive option for protein modification
chemistry, enabling the synthesis of a wide range of non-natural polypeptide derivatives. Attempts
at understanding how these enzymes recognize and bind substrates are integral to furthering their
usefulness in protein engineering and, potentially, treatment of bacterial diseases. However, the
variable substrate specificity and activity between homologs of these enzymes is not yet fully
understood. Of specific interest to us is sortase A from Streptococcus pneumoniae (SrtApneu), as it
demonstrates a broad substrate tolerance not observed in other sortase A homologs.
Correspondingly, we have made advances towards characterizing a substrate bound structure of
SrtApneu in an effort to further understand its unique substrate promiscuity, deviating from the
canonical LPXTG sorting signal. Our strategy initially involved generating a non-cleavable
peptide analog capable of docking into the active site, however, synthesis of a ketomethylenelinked dipeptide isostere and its insertion into a peptide via solid phase peptide synthesis proved
to be more challenging than we anticipated. We revised our approach by designing a substrate
harboring an LPACG sorting motif. Peptide preparations with a thiopyridine leaving group
favorably facilitated disulfide bridging between the active site and sorting motif cysteines,
allowing for elucidation of a SrtApneu structure displaying key interactions that allow the enzyme
to recognize a wide-variety of substrates. To this end, we have utilized x-ray crystallography and
solution NMR in an attempt to characterize SrtApneu with a bound substrate analog. Although we
were unsuccessful, this work has established a foundation for future efforts toward determining
the substrate-bound structure of SrtApneu.
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Chapter 1 – Introduction
1.1 Protein Engineering - Advantages of Chemoenzymatic Modification
Contemporary pursuits toward endowing proteins with unnatural or non-canonical
functionalities, known as protein engineering, has garnered significant attention across academic,
industrial and medical applications.1–4 Protein engineering efforts were historically limited to
molecular biology techniques to install protein modifications genetically, which were applied
through single-point mutations as well as frameshift sequence insertions and deletions.5 The
modern utility of mutagenic techniques, such as directed evolution and unnatural amino acid
incorporation, have dramatically broadened the variety of protein modifications, however, these
methods continue to be burdened by substantial time and cost investments.6–10 In contrast, protein
modification through novel direct chemical ligation strategies is a relatively quick and costeffective way of engineering proteins. This bioconjugation technique takes advantage of the
natural reactivity of sterically unencumbered amino acid side chains (i.e. lysine, cysteine, glutamic
and aspartic acids), which is optimal for generating proteins with non-natural modifications.11–15
While these contemporary modification strategies have revolutionized protein engineering,
continuing to expand the scope and efficacy of direct protein bioconjugation is critical for the
advancement of several fields, including fundamental biochemistry, the design of protein
therapeutics, and the generation of new biomaterials.

Chemoenzymatic modification of proteins has provided an attractive alternative to sitedirected mutagenesis and direct chemical modification strategies. This bioconjugation technique
has been utilized in a variety of instances, including the production of fluorescently labeled
proteins for live-cell trafficking, antibody-drug conjugates for site-specific payload delivery, and

adhering protein to nanoparticles.16–18 In chemoenzymatic modification, a sequence of amino acids
is recognized by the modification enzyme, which results in the site-specific attachment of the
desired moiety (Figure 1). If an endogenous protein target does not possess the required
recognition sequence, which is often the case, then a recognition site must be added, typically
using site-directed mutagenesis.19 There is a continuously expanding assortment of modifications
that can be installed using chemoenzymatic modification strategies, along with a growing catalog
of enzymes able to catalyze these processes.

Protein Target

Modified Protein

Modification

Modification Enzyme
Figure 3. Generic Schematic of Chemoenzymatic Protein Labeling. A protein (left) harboring a binding
motif is recognized by the modification enzyme, then the modification is covalently attached to the protein
target (right).

A notable example of an enzyme used in chemoenzymatic strategies is formylglycine
generating enzyme (FGE), which recognizes a CXPXR sequence of amino acids, then modifies
the cysteine residue to a formylglycine reaction handle commonly utilized for generating stable
oxime ligation products.20–22 Lipoic acid ligase has seen use through similar bioorthogonal ligation
approaches, wherein this enzyme canonically functions to adhere lipoic acid to the ε-amine of
lysine side chains within the primary sequence of its target protein. 23 Interestingly, this
promiscuous enzyme has demonstrated the ability to install a diverse variety of substrates, notably
azide and alkyne containing click handles, which has significantly broadened the scope of site-
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specific modifications that can be installed using lipoic acid ligase.24 Biotin ligase manifests a
similar behavior, where it covalently attaches a biotin residue to the ε-amine of the lysine side
chain within its target recognition sequence.25 Biotin-based protein engineering has attracted
attention due to its robust function as a site-specific tag for binding streptavidin or avidin
containing biomolecules, including functionalized nano-particles or quantum dots, with
exceptional specificity and pico-molar affinity.26,27

The sortase enzyme family has also been extensively studied for its utility in protein
modification. Sortases are endogenous to Gram-positive bacteria, where they function as
transpeptidases through a catalytic mechanism involving a nucleophilic cysteine within the
enzyme’s active site.28–30 Sortases are separated into distinct classes (A-F) based on their unique
contrasting structural and biochemical traits.31,32 Class A sortases (SrtA) have demonstrated the
most relevance to protein engineering, having been recombinantly expressed with a truncated Nterminus to remove the transmembrane domain, which has resulted in a soluble derivative of SrtA
for in vitro ligation reactions. In vivo, SrtA performs an essential “housekeeping” role in
maintaining the extracellular environment by anchoring a variety of proteins to the cell wall.33–36
Proteins appended to the extracellular matrix by SrtA are key virulence factors, including collagen
adhesion proteins as well as fibronectin and immunoglobulin binding proteins, that are responsible
for bacterial cell colonization and evading host immune detection.37–42 The in vivo function of SrtA
has been highlighted as a viable drug target in Gram-positive bacteria, as studies have reported a
dramatically reduced virulence of SrtA knockout Gram-positive bacterial strains.43–47 As the
catalog of ineffective antibiotic drugs continues to rapidly expand, it has become imperative to
develop an in-depth understanding of sortase structure and enzymology to further the development
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of novel therapeutics while simultaneously providing insight into their role in protein
engineering.48

Figure 4. Overview of SrtA in vivo mechanism on surface of Staphylococcus aureus.

Sortase A enzymes share a common mechanism of action involving the recognition of a
five amino acid sequence, which will hereafter be referred to as a “sorting motif”. The most
common sorting motif for SrtA enzymes is the LPXTG sequence, where X is any amino acid.31,32
However, it is now known that different SrtA homologs can recognize a number of variations of
the standard LPXTG sequence. Sortase A from Staphylococcus aureus (SrtAstaph) recognizes a
protein substrate harboring an LPXTG sorting motif (Figure 2).36 Next, the active site cysteine
cleaves the amide bond between threonine and glycine, which releases the excised C-terminal
fragment from the substrate. A transient acyl enzyme intermediate is formed through this process,
and the scissile thioester linkage is subsequently intercepted by nucleophilic attack of the Nterminal amine of a pentaglycine peptide of lipid II anchored to the peptidoglycan matrix.
Reconstitution of the amide bond linkage fuses the protein to the peptidoglycan, at which point the
protein substrate is released from the active site and the enzymatic potency of SrtAstaph is restored
for additional catalytic cycles.
4

In vitro, SrtA enzymes have been utilized extensively in protein engineering chemistry due to their
ability to catalyze site-specific modifications at the sorting motif. Recent efforts that have used
this approach include conjugating proteins and peptides to fluorophores, nanoparticle solidsupports, synthetic peptides, surfaces of live cells and other proteins (Figure 3).49–53

Figure 3. Protein modification using model SML.

This by no means encapsulates the full breadth of modifications that can be achieved using
sortase-mediated ligation (SML), and we refer the reader to other excellent reviews for more
comprehensive discussions of SML applications.54–58 One of the key factors in the versatility of
SML is the ability of users to control which reaction partner is functioning as the LPXTG-substrate
and which is serving as the reaction nucleophile.59–61 In doing so, one is able to use SML for
appending modifications to exposed C- and N-termini, and in some cases sterically unencumbered
secondary structures. To date, the majority of these SML studies have utilized wild-type SrtAstaph.
However, over the past decade a number of efforts to improve the properties of SrtAstaph have
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resulted in evolved mutants demonstrating improved reaction rates, non-canonical substrate
tolerances, and Ca2+ cofactor independence.62–65 These evolved variants now provide a range of
sortase derivatives that can be selected for specific applications.

1.2 Expanded Substrate Tolerance of Sortase Homologs
As noted above, there exists a diverse archive of published protein engineering applications
utilizing sortase-mediated ligation, which is continually expanding along with contemporary
efforts to circumvent limitations historically associated with this technique. Notably, issues
associated with SML include the slow reactions rates of ligations using SrtAstaph, reaction
reversibility, strict substrate specificity, and a narrow scope of compatible amine nucleophiles.66–
68

Of relevance to this thesis, there have now been reported multiple studies on expanding the

substrate scope of SML using either SrtAstaph mutants or other naturally occurring sortase
homologs.63,64,69–71
Table 2. Substrate specificity of Sortase A mutants and wild-type homologs.

Bioinformatic investigations of SrtA homolog specificities through the CW-PRED2
genome alignment algorithm has revealed a universal preference for LPXTG motifs.65,72 In vitro
analysis of SrtA preferences with computationally derived peptide substrates have revealed
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discrepancies between actual and predicted SML compatible sorting sequences (Table 1). Notably,
Kruger et al. have experimentally demonstrated that SrtAstaph tolerates LPXXG substrates, and
exhibits a preference for glycine in the 6th position, outside of the canonical LPXTG sorting
motif.73 Phage and yeast display directed evolution studies have generated evolved variants of
SrtAstaph with alternative substrate preferences.64,69 These SrtAstaph mutants have exhibited a
relaxed substrate tolerance for residues in 1st, 2nd and 4th position.

Randomization of the β6/β7 loop among SrtAstaph mutants revealed evolved variants
selective for FPXTG or APXTG motifs.64 Rather than genetically modifying the substrate
preferences of SrtAstaph, others have taken the approach of exploiting the natural reactivity and
specificity of different SrtA homologs.70,71 The model enzyme for SML has historically been wildtype SrtAstaph, however, a notable endogenous SrtA homolog from streptococcus pyogenes
(SrtApyogenes) has revealed advantages beyond the utility of SrtAstaph. SrtApyogenes is capable of
recognizing a diverse catalog of substrates, which has enabled a multifaceted approach to sitespecifically modify different regions within a single protein target.19 Furthermore, SrtApyogenes is
capable of generating isopeptide bonds by accepting ε-amine of lysine, as well as processing the
N-terminal amines of glycine, serine, and even D-asparagine residues.74 In general, streptococcal
sortases have exhibited promiscuous substrate preferences, and an unprecedented tolerance for
LPXLG motifs, which may be useful for SML reactions.71 To date, sortase A homologs employed
for SML reactions represent only a fraction of the thousands of sortase genes encoded by genomes
across the bacterial kingdom.75,76 Therefore, there exists an untapped potential for harnessing the
reactivity of sortase A homologs to broaden the scope of applicable SML substrates. Our lab has
highlighted this concept by determining the substrate preferences of eight naturally occurring SrtA
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homologs, each exhibiting a preference for residues across each position along the sorting motif.70
Positions 4 and 5 displayed significant deviation from the canonical LPXTG sorting motif, where
many SrtA homologs preferred substrates with several different amino acids in the 5th position.
Notably, sortase A from Streptococcus pneumoniae (SrtApneu) demonstrated the broadest substrate
tolerance of non-canonical amino acids in the 5th position (Figure 4).

Figure 4. Comparison of substrate preferences for the 5th position of the sorting motif among SrtA
homologs.70 These values represent % conversion of substrate to excised fragment. No cleavage was
observed for X = P, T, I, D, E, R, K, H.

Although SrtApneu recognizes a variety of sorting motifs, high performance liquid
chromatography (HPLC) and mass spectrometry (MS) analyses of product conversion from model
SML reactions revealed a strong preference for an LPATA substrate in vitro, which is strikingly
different than the LPETG preference for SrtAstaph. The SrtA reactivity and specificity trials we’ve
published may persuade the reader to believe that SrtA is not appropriate for SML applications
based on the suboptimal product conversion of various substrates. However, the data presented is
reflective of unoptimized reactions, where even the lowest substrate conversion can be drastically
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improved by redesigning the reaction conditions. The utility of SrtA pneu has provided an
opportunity to bolster the applicability of SML protein engineering by broadening the scope of
substrate targets. As a result, SrtApneu has potentially reduced the necessity to mutagenically
implement a sorting motif into protein targets, which improves the compatibility of SML for
endogenous proteins. The unique substrate promiscuity of SrtApneu has potentiated an interest
toward elucidating active site residues responsible for dictating the mechanism of recognition. A
deep understanding of these interactions on a molecular level would likely provide insight to this
phenomenon, which will advance our understanding of sortase enzymology and sortase-mediated
chemistry. The structure of SrtApneu has not been published, which has compelled our efforts
toward an in-depth analysis of SrtApneu substrate recognition through structural characterization.

1.3 Substrate Binding and Structural Characteristics of SrtA Homologs
Multiple structures of various SrtA homologs have been published over the last decade,
which were either characterized by X-ray crystallography or solution nuclear magnetic resonance
(NMR) spectroscopy. Published structures of SrtAstaph have aided in developing an improved
understanding of enzyme-substrate binding interactions with residues in the sorting motif, and
insight into the reverse protonation mechanism instigating transpeptidation reactions.77,78
Published structures of SrtA homologs manifest an 8-stranded β-barrel fold, which is a conserved
feature across SrtA enzymes.30 Strands comprising the β-barrel are flanked by a series of alpha
and 310 helices, as well as disordered loops varying in size and position among homologs.31,33,79–82
In general, SrtA enzymes share an evolutionarily conserved active site housing three catalytic
residues; a cysteine to establish a transient thio-acyl linkage, a histidine to facilitate thiolate
formation, and an arginine thought to provide hydrogen bonding to stabilize active site residues
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essential for catalysis.33,83 In the case of SrtAstaph, the floor of the active site, or binding groove, is
formed by β4 and β7 loops and the adjacent walls are composed conjoining loops, and helices. The
binding pocket adopts the appearance of a bent “L” shape, which may justify the necessity for
proline in the 2nd position of the sorting motif as it situates the amide bond linking 4th and 5th
position residues towards the active site cysteine.78 The non-polar carbon fork of the 1st position
leucine establishes hydrophobic contacts with residues in the β6/β7 loops, and the 2nd position
proline is buried within a hydrophobic cleft formed by residues in β4 and β7 strands. The 3rd
position alanine maintains distant hydrophobic interactions with the H1 helix, which may provide
a rationale for the indiscriminate preference for residues in this position as there exists ample space
for cumbersome side chains. The 4th position threonine pushes a nearby tryptophan residue
(Trp194) out of the active site, which situates the active site cysteine in proximity to the scissile
peptide bond. Preservation of threonine is critical for this mechanism, as substrates substituting
glycine in the 4th position are unreactive. The 5th position glycine is predicted to associate with the
β7/β8 loop, which hypothetically undergoes a distinct transition to a structurally ordered
conformation upon substrate docking.78,84–86 Preferential recognition of the 5th position residue is
anticipated to be partially dependent on the length of the β7/β8 loop. SrtAstaph has a relatively large
β7/β8 loop compared to other homologs, which may condone the stringent selectivity for glycine
in the 5th position of the sorting motif. After substrate docking is facilitated, nucleophilic attack
of the scissile peptide bond by the active site cysteine repositions the β7/β8 loop further from the
binding pocket, revealing a sterically unencumbered site for incoming nucleophiles.78
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The substrate bound SrtAstaph complex published by Suree et al. has constructed a
framework for interpreting the role of each residue positioned along the LPAT substrate analog
and deciphering crucial interactions with residues housed within the active site (Figure 5).78

Figure 5. (A) Solution NMR structure of SrtAstaph. Arginine (cyan), cysteine (magenta), and histidine
(blue) stick structures represent catalytic residues in the enzyme active site. (B) Predicted structure of
SrtApneu based on a one-to-one threading model of SrtApyogenes (PDB ID: 3NF7) from the Phyre2
structural prediction server. (C) Solution NMR structure of the SrtAstaph active site with a bound LPAT*
substrate analog (PDB ID: 2KID). Side chains of residues comprised within the active site are shown
as stick structures, highlighting several hydrophobic interactions stabilizing the substrate-bound state.
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Unfortunately, this systematic model fails to provide a holistic depiction of SrtA substrate
recognition and binding since the substrate analog only contains the first four amino acids (LPAT)
in the sorting sequence. As a result, identifying active site residues that interact with the 5th position
residue of a target sorting motif is challenging based on this model. However, Suree and coworkers
illuminated regions in SrtAstaph thought to be responsible for recognizing the 5th position residue
in the sorting motif as well as coordinating entry of the incoming nucleophile.

Figure 6. Sequence alignment of selected SrtA homologs. The regions of greatest difference (boxed)
correspond to the regions highlighted in the structure (right), indicating the least sequence homology
on the structural features predicted to interact with the 5th position of the sorting sequence. The structure
(right) is a surface representation of SrtAstaph bound to a substrate analog LPAT* (PDB ID: 2KID).
Residues highlighted in magenta were determined to interact with the incoming nucleophile by analysis
of peak perturbation during an 15N-HSQC monitored titration of SrtAstaph with triglycine. These residues
are primarily situated around the region of the binding pocket and are predicted to interact with the Cterminus of the sorting signal.

Three regions in SrtAstaph displayed significant alterations in their backbone resonances in
the presence of a triglycine nucleophile, which was monitored using

15

N heteronuclear single

quantum coherence (HSQC) NMR (Figure 6).87 Residues harbored within these regions are likely
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contacting the 5th position residue of the sorting motif, which suggests that they are critical for
substrate recognition. Sequence alignments of SrtA homologs indicated distinct differences in
primary structure within these regions, which provides a rationale for the diverse tolerance of
various residues in the 5th position. This evidence coincides with our experimental findings, where
SrtA homologs demonstrated a variety of preferences for the 5th position residue. Supplementary
assessments are necessary to establish a more thorough understanding of SrtA substrate
recognition.

Figure 7. (A) The 3D domain swapped dimer of SrtApneu (PDB ID: 4O8L). (B) A domain swapped
monomer from the dimeric structure of SrtApneu. (C) Predicted structure of SrtApneu based on a one-toone threading model of SrtApyogenes (PDB ID: 3FN7) from the Phyre288 structural prediction server. In
both (B) and (C) structures, the red colored regions resemble the domain swapped portion of the
structure shown in (A).

A 3D domain swapped structure of SrtApneu has been deposited in the Protein Data Bank
(PDB ID: 4O8L), but monomeric enzyme with (or without) bound substrate has not yet been
characterized (Figure 7). A structure of monomeric SrtApneu bound to a substrate may distinguish
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novel features that are responsible for its unique substrate tolerance, similar to aforementioned
efforts toward determining which active site residues contribute to substrate recognition in
SrtAstaph. Phyre2 structural prediction algorithms have served as a preliminary means of
determining which residues perpetuate the promiscuous substrate tolerance of SrtApneu.88 Structure
predictions suggest that SrtApneu to has a smaller β7/β8 loop than SrtAstaph, which may confer a
broader substrate tolerance, as this loop region is thought to be important for recognizing the 5th
position residue of the sorting motif.

1.4 SrtApneu Enzyme Activity as a Function of Oligomeric State
The structure of monomeric SrtApneu has yet to be determined, however, the dimeric form
of the enzyme has piqued our interests toward understanding the mechanism of assembly in vivo
and in vitro, as well as its role on enzyme activity. In previous SrtApneu studies, we sought to
evaluate the catalytic activity of both dimeric and monomeric forms of the enzyme.70 These
multimers were identified in an IMAC elution of purified SrtApneu by native-PAGE, where
numerous distinct bands were observed, as opposed to SDS-PAGE analysis displaying a single
band. In model SML studies, we hypothesized that monomeric SrtApneu was an active form of the
enzyme, whereas multimeric forms were thought to be an inactive form, based on their activity in
the presence of an Abz-LPATAG-K(Dnp) peptide substrate and a potent hydroxylamine (NH2OH)
nucleophile (Figure 8). Model SML reactions utilizing multimeric SrtApneu rapidly plateaued with
minimal product formation (21% product conversion). Conversely, identical reactions involving
monomeric SrtApneu achieved significantly higher product formation (95% product conversion).
To confirm our suspicions, size exclusion fast protein liquid chromatography (SE-FPLC) was
utilized to confirm the presence of all SrtApneu assemblies. The spectra revealed multiple species
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varying in molecular weight, and native-PAGE bands of respective fractions travelled identical to
native-PAGE bands of a SrtApneu heterogeneous mixture.

Figure 8. RP-HPLC analysis of model SML reactions demonstrating the difference in activity
between monomeric (top) and multimeric (bottom) SrtApneu preparations.70

Bacterial expression of a truncated SrtApneu clone (Δ80) generated substantial amounts of
inactive enzyme, thus it became imperative to explore options allowing us to regenerate fully
active monomeric SrtApneu.70 We initially proposed the idea of subjecting SrtApneu to conditions
eliciting the disassembly of all SrtApneu multimers, followed by the refolding of denatured SrtApneu
to monomeric enzyme. Our original hypothesis speculated that SrtApneu dimerization is an
equilibrium driven process, where acute concentrations of enzyme may shift the equilibrium
toward an energetically favorable dimeric fold. Attempts to incubate serial diluted samples at room
temperature sought to evaluate this possibility. Contrary to our rationale, the intensity of a dimeric
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SrtApneu band in a native-PAGE gel remained unaffected. We proposed the possibility that SrtApneu
dimerization is co-translational phenomenon, where artificially elevated concentrations in-vivo
may instigate a dimeric fold. If true, we anticipated that dismantling SrtApneu assemblies during
purification, followed by refolding under native conditions, may provide an opportunity for
SrtApneu to reassemble into monomeric enzyme. A denaturing agent capable of disrupting any
intermolecular interactions, namely domain swapping contacts, was implemented in our IMAC
purification buffers. Specifically, we employed an initial denaturing IMAC purification using 8 M
urea, where E. coli cells were lysed under denaturing conditions, the protein was purified from
clarified lysate in denaturing buffer via IMAC, followed by a rapid dilution of denaturing eluate
in non-denaturing buffer to refold monomeric enzyme. The non-denatured diluted protein was
reconcentrated by a non-denaturing IMAC purification, and eluted fractions were further purified
by SE-FPLC to isolate residual dimers from reassembled monomeric enzyme. We also added
tris(carboxyethyl)phosphine (TCEP), a non-sulfurous reducing agent, to our IMAC purification
buffers to disfavor cysteine disulfide bridging between monomers and preserve the reduced form
of the thiol. Overall, our enzyme refolding protocol in tandem with SE-FPLC enrichment
significantly improved SrtApneu monomer recovery (Figure 9). Furthermore, the regenerated
SrtApneu monomer performed identical to previous model SML reactions, where 95% conversion
was observed for the refolded enzyme.
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Figure 9. A comparison of standard vs. refolded SrtApneu preparations via SE-FPLC (left). NativePAGE analysis of isolated monomeric (M) fractions and dimeric (D) fractions by SE-FPLC (right).

Supplementary investigations have revealed the presence of both monomeric and dimeric
forms of SrtAstaph in vivo and in vitro.89–91 The in vitro catalytic activity of monomeric SrtAstaph
has been evaluated by Lu and coworkers, where ligation reactions with homodimeric preparations
demonstrated superior product conversion compared to monomeric enzyme. In contrast, the
insertion of a non-dimerizing SrtAstaph mutant in a knockout strain of S. aureus by Zhu et al.
resulted in an increased presence of sortase-catalyzed surface anchored proteins in vivo, which
provides evidence in support of a catalytically active SrtAstaph monomer. In vivo observations of
SrAstaph activity as a function of oligomerized state are in clear contrast to in vitro studies, but
coincide our evidence indicating monomeric SrtApneu is the catalytically active form in vitro. The
pervasive dimerization among SrtA homologs has raised questions regarding the biological
significance of these dimers, as they are anticipated to serve as a means of regulating enzyme
deactivation when extracellular protein appendage is unnecessary.89,91 This proposed mechanism
of regulation is not unfounded, as there exists many enzymes (i.e. phospholipase) that are governed
in this fashion.92 Although interplay between monomeric and dimeric forms of SrtAstaph and
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SrtApneu has been evaluated, similar investigations have not been geared toward other SrtA
homologs.

1.5 Overview of Project Goals
The modern utility of sortases as a tool for protein engineering has broadened the
accessibility of site-directed ligation chemistry, which is substantiated by previous efforts toward
understanding substrate tolerance among sortase homologs and the circumvention of limitations
historically plaguing sortase-mediated ligation techniques. The continued development of this
system is hinges upon our ability to develop a structure-function relationship among sortases in an
effort to improve our knowledge of substrate recognition among homologs with diverse substrate
tolerances. To this end, the long-term goal of this project is to determine the structure of SrtApneu
covalently docked with a peptide inhibitor as a means to identify novel interactions with activesite residues prompting a unique promiscuous substrate tolerance. As described in this thesis,
preliminary investigations of monomeric SrtApneu structure involved protein crystallography
followed by X-ray diffraction. Concurrently, we have attempted to construct a non-cleavable
ketomethylene-based sorting motif analogs in an effort to prolong occupancy within the SrtApneu
active site. Sorting motif substitution of 4th and 5th position residues with ketomethylene dipeptide
was anticipated to mimic the performance of canonical SrtApneu substrates. Unfortunately, the
challenging synthesis of a solid-phase ready ketomethylene dipeptide and the rapid degradation of
ketomethylene-based substrates depreciated effectiveness of this approach. Correspondingly,
we’ve redesigned our canonical SrtApneu substrate sorting motif with a cysteine residue in the 4th
position. We believe this substrate analog will establish a disulfide linkage with the active site
cysteine, allowing for elucidation of key interactions between the enzyme and residues positioned
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along the sorting motif. Identification of substrate bound SrtA complex via LC-ESI-MS has
propelled our efforts toward determining the structure using HSQC NMR.

Chapter 2 – Screening Studies for X-ray Crystallography of SrtApneu
2.1 Preparation of SrtApneu for Crystallization
Prior to screening crystallization conditions, it was first necessary to generate suitable
preparations of the SrtApneu enzyme that were monomeric. To this end, an expression vector
encoding a truncated version of SrtApneu lacking the first 80 residues (hereafter referred to as
simply SrtApneu) and fused to an N-terminal His6 tag was obtained. In this construct, the
hydrophobic transmembrane domain was removed to increase the in vitro solubility of SrtApneu in
aqueous buffers. A glycerol stock of transformed E. coli BL21 (DE3) was used to express SrtApneu
using standard molecular biology techniques. After denaturing cell lysis using 8 M urea, the
enzyme was separated from the cellular debris via centrifugation, then isolated from the
supernatant using immobilized metal affinity chromatography (IMAC) under denaturing
conditions (Figure 10, lanes 2-6). The denatured protein eluate from IMAC was then diluted tenfold into a non-denaturing buffer (50 mM Tris pH 7.5, 150 mM NaCl, 1 mM TCEP) to refold
SrtApneu, then repurified via IMAC under non-denaturing conditions to isolate soluble SrtApneu
(Figure 10, lanes 7-10). The sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDSPAGE) analysis of the refolded SrtApneu eluate revealed an intense band near 26 kDa, which was
consistent with the calculated 20.1 kDa molecular weight of SrtApneu. This SDS-PAGE gel also
showed the presence of a ~50 kDa SrtApneu dimer that persisted in the sample despite reducing and
denaturing preparations.
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Figure 10. SDS-PAGE analysis of a SrtApneu IMAC/refolding purification scheme: (1) Protein
molecular weight ladder, (2) cell lysate supernatant, (3) flow-through fraction of IMAC column under
denaturing conditions, (4) denaturing wash, (5) 1st denaturing elution fraction, (6) 2nd denaturing elution
fraction, (7) flow-through fraction of IMAC column following dilution of SrtApneu in non-denaturing
buffer, (8) non-denaturing wash, (9) 1st non-denaturing elution fraction, (10) 2nd non-denaturing elution
fraction.

In order to separate monomeric SrtApneu from higher order aggregates, the refolded protein
solution was subjected to size exclusion chromatography (SEC). Monomeric fractions were
collected and pooled, and analysis by analytical SEC revealed that final the protein preparation
consisted of >85% monomer (Figure 11). Electrospray ionization mass spectrometry (ESI-MS) of
the final monomer preparation reported a mass of 20,144 Da, in excellent agreement with the
calculated molecular weight of 20,145 Da for SrtApneu (Figure 11). Taken together, SEC and ESIMS analyses provided evidence for a predominantly monomeric batch of SrtApneu, which was
subsequently concentrated to ~6 mg/mL for protein crystallization trials.
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Figure 11. SEC traces of IMAC purified, refolded SrtApneu (A) and collected monomeric fractions (B).
A deconvolved mass spectrum (C) of SrtApneu generated from the (D) raw ESI-MS spectrum of the
purified enzyme.
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2.2 Summary of Crystal Screening Efforts
With a monomeric batch of SrtApneu in hand, we turned our attention to screening
conditions for crystallization of this enzyme. Initially, this involved utilizing vapor-drop diffusion
methods for generating crystals. The concentrated stock of 6 mg/mL monomeric SrtApneu was
screened against PEG/Ion2 and Index screening condition kits, each containing 48 and 96 different
conditions, respectively. Four room temperature conditions from the Index screening kit produced
a variety of crystal morphologies including wafer, rod, and asymmetric crystals (Table 2, Figure
12).
Table 2. Preliminary screening conditions resulting in
crystal formation (pH 5.5, 25% PEG 3350, RT).

Figure 12. Crystals formed by
screening conditions in Table 2.

These crystallization conditions shared numerous similarities, which suggested that BisTris, pH 5.5, and polyethylene glycol (PEG) 3350 were promising components for inducing
SrtApneu crystallization at room temperature. Based on this analysis, we sought to optimize these
conditions by determining SrtApneu nucleation dependence as a function of pH and PEG 3350
concentration (Figure 13).
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Figure 13. Crystal optimization as a function of pH and PEG 3350. The arrow represents the observed
pattern of crystal formation, appearing more frequently as pH decreases and PEG 3350 increases.

After two weeks, we observed the presence of crystals in conditions with low pH (4.5-5.5)
and relatively high PEG 3350 concentration (24-26%). Microscopic investigation of crystals
formed in the presence of these conditions revealed relatively small crystals that did not appear to
have the defined 3D structure (i.e. hexagonal prism) of diffractable protein crystals.

Crystal screening was continued by maintaining 25% PEG 3350 and pH 4.5 or 5.5,
however this time adjusting the concentrations of Bis-Tris (0.05-0.30 M) and other tuning salts
(0.05-0.40 M). Hits were detected that produced crystals after two weeks, which essentially
replicated the appearance of crystals grown in the previous pH/PEG optimization trial. Unlike the
pH/PEG optimization trial, there was not a noticeable pattern indicating which salt/buffer
concentrations favored crystal formation. This suggested that crystal growth and morphology was
neither dependent on Bis-Tris nor tuning salt concentrations. It should be noted that each
optimization trial was designed to replicate the initial screening conditions (#1-4) as a control,
however, the reproducibility of crystals generated by these conditions was inconsistent. Although
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the crystals we had generated were far from ideal for
structure determination, we attempted to diffract our top

Table 3. Diffracted crystals formed by
conditions A-E (pH 5.5, 25% PEG 3350,
RT).

candidates to determine whether we were generating salt
or protein crystals (Table 3). Every crystal subjected to
X-ray diffraction analysis displayed a prominent “ice
ring” pattern, which occurs when the protein crystal is
thawed and refrozen during transfer to the goniometer
head of the diffractometer. Beyond this artifact, we
didn’t observe any indication of a diffraction pattern corresponding to a proteinaceous crystal.

We next tried crystallization conditions that were not included in either the PEG/Ion2 or
Index crystal screening kits. Our previous screening efforts suggested that chloride-containing
salts may promote crystal formation. Therefore, additional trials with potassium chloride (KCl),
ammonium chloride (NH4Cl), or calcium chloride (CaCl2) tuning salts (0.05-0.40 M) in addition
to Bis-Tris (0.05-0.30 M) were prepared. However, these did not demonstrate any capacity to grow
diffractable crystals. We also attempted to modulate the standard 1:1 (2 µL drop) ratio of enzyme
loading to mother liquor. Since we had observed some protein aggregation during pH/PEG
optimization trials, we anticipated that a lower enzyme loading relative to mother liquor would
slow nucleation and allow for improved crystal packing. Unfortunately, no crystals were observed
using diluted SrtApneu preparations even months after plating.

Finally, several months after our initial pH/PEG optimization trials, we did observe the
presence of well-defined opalescent crystals in a well containing a replicate of the #4 screening
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condition (0.1 M BT, pH 5.5, 0.2 M MgCl2, 25% PEG 3350, RT). We attempted to loop these
crystals, however, they had formed contacts with neighboring crystals and we were unable to
effectively loop a single crystal without fracturing their structural integrity. In consideration of this
promising result, we focused on optimizing condition #4 to recreate, and possibly improve, the
iridescent crystals observed previously. Through the advice of our collaborators, we decided to
optimize condition #4 by modulating PEG 3350 concentration as well as enzyme to mother liquor
loading ratio. Several weeks after, we observed protein aggregation across over half of the
preparations, and no sign of crystal formation.

In summary, while we have been able to generate a monomeric preparation of SrtApneu, we
have yet to identify conditions that produce crystals suitable for structure determination. Given the
fact that multiple sortases have been successfully characterized using X-ray crystallography, we
anticipate that monomeric SrtApneu will ultimately be amenable to X-ray characterization, however
additional crystallization condition screening is required. In addition, it may be necessary to
redesign the protein construct itself, as the 80 residue truncation or the presence of the N-terminal
His6 tag may not be optimal for crystal formation.

Chapter 3 – Preparation and NMR Characterization of 15N-labeled SrtApneu
3.1 Preparation of unlabeled TEV-SrtApneu and 1D 1H-NMR Analysis
In parallel with our efforts to generate X-ray quality crystals of SrtApneu, we also began
studies aimed on elucidating the enzyme’s 3D structure using solution NMR. To this end, we first
generated a new stock of SrtApneu in order to monitor its stability using one dimensional 1H-NMR.
Anticipating that we may need to remove the N-terminal His6 tag, a new clone of SrtApneu (TEV-

25

SrtApneu) was obtained, which included a TEV cleavage site between the His6 tag and the catalytic
domain. Although numerous publications have demonstrated that His6 tags typically to do not
perturb protein folding and function, we had contemplated that our inability to effectively
crystallize SrtApneu may be a repercussion of the flexible His6 tag and thus the TEV cleavage site
was included as an option.

Figure 14. (Left) SDS-PAGE analysis of non-denaturing IMAC purification of TEV-SrtApneu: (1)
Protein molecular weight ladder, (2) cell lysate supernatant, (3) flow-through fraction of IMAC column
under non-denaturing conditions, (4) wash, (5) 1st non-denaturing elution fraction, (6) 2nd nondenaturing elution fraction. (Right) Native-PAGE analysis of non-denaturing IMAC purification of
TEV-SrtApneu: (A) cell lysate supernatant, (B) flow-through fraction of IMAC column under nondenaturing conditions, (C) wash, (D) 1st non-denaturing elution fraction, (E) 2nd non-denaturing elution
fraction.

Interestingly, and in contrast to the SrtApneu clone used for crystallization trials, we found
that TEV-SrtApneu yielded sufficient quantities of active monomer without the need for refolding.
As shown in Figure 14, a band with an appropriate molecular weight was observed following
simple, non-denaturing IMAC purification, and native-PAGE analysis of the same purification
revealed significant quantities of both a monomer and dimer. An SDS-PAGE analysis of the
elution fraction revealed a high intensity band at ~26 kDa of SrtApneu as well as residual higher
molecular weight polypeptides structures (Figure 14, lane 5). Additionally, we noticed a signature
pair of bands representing monomeric (bottom) and dimeric (top) enzyme in a native-PAGE gel.
26

Figure 15. SEC traces of IMAC purified TEV-SrtApneu (A) and collected monomeric fractions (B). A
deconvolved mass spectrum (C) of TEV-SrtApneu generated from the corresponding raw ESI-MS
spectrum (D).

As noted above, a denaturing IMAC/refolding purification procedure was not applied to
this protein expression, which provides a rationale for the relatively large band of dimer relative
to monomer. In order to isolate the desired monomer of TEV-SrtApneu, we relied on a newly
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acquired HiPrep 16/60 Sephacryl 200-HR size exclusion column, which provided excellent
separation of the TEV-SrtApneu monomer from higher order assemblies (Figure 15A,B). Mass
spectrometry also confirmed that the isolated protein had the expected molecular weight (Figure
15C,D).

Figure 16. RP-HPLC analysis of model SML reaction using TEV-SrtApneu at 0 hr (Black) and after 150
minutes (Blue). (A) Abz-LPATGG-K(Dnp) substrate. (B) Abz-LPATG-NHOH product. (C) GGK(Dnp) excised fragment.

To confirm that monomeric TEV-SrtApneu was active, our preparation was subjected to a
model sortase-mediated ligation (SML) reaction using an Abz-LPATGG-K(Dnp) peptide substrate
and a strong H2NOH nucleophile to assess in vitro catalytic activity. Previous work from our lab
revealed that monomeric SrtApneu was catalytically active while dimer was inactive, so we
anticipated our enzyme stock to behave accordingly. The reactions were analyzed by reverse phase
liquid chromatography (RP-HPLC) every 30 minutes during a 150-minute incubation period at
room temperature. The UV/Vis chromatogram for the TEV-SrtApneu monomer revealed a ~65%
conversion of substrate to modified product, which we deemed as sufficiently active compared to
the minimal (<5%) product formation of inactive dimer even after a 24-hour incubation (Figure
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16). Overall, these analyses provided evidence that the monomeric form of TEV-SrtApneu was
indeed an active form of the enzyme, and the form of the enzyme that would be of interest for
further structural characterization.

Figure 17. 1D 1H-NMR analysis of monomeric SrtApneu-TEV over the course of several days.

A stock of SrtApneu was concentrated to 450 µM, then used to prepare a 1H-NMR sample
including deuterated water (D2O, 10% v/v), ethylenediaminetetraacetic acid (EDTA) and sodium
azide (NaN3). This sample was subjected to several rounds of 1H-NMR analysis (512 scans) over
the course of eight days (4 °C) to monitor conformational stability and report signs of degradation
(Figure 17). The spectral consistency observed among all acquisitions, in particular within the
amide N-H region (6-10 ppm) and the aliphatic side chain region (1-3 ppm) suggested that the
TEV-SrtApneu monomer was stable over lengthy periods of time, and presumably not degrading or
aggregating into higher order structures.
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3.2 Expression and Purification of 15N-labeled TEV-SrtApneu
Having established that TEV-SrtApneu remained sufficiently stable in solution, we then
began generating a stock of isotopically labelled (15N) enzyme for two-dimensional NMR
characterization. A glycerol stock of transformed E. coli BL21 (DE3) was used to express
TEV-SrtApneu using a minimal media expression protocol in order to incorporate the
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15

N

N label.

Briefly, this procedure involves using an overnight seed culture grown in standard LB to initiate a
large-scale growth, which should be gently centrifuged after an OD600 of 0.5 is reached. The
pelleted cells are then resuspended in a wash solution to remove residual nutrient rich media, which
must be performed in a timely manner to avoid significant cellular arrest. The cells are then
resuspended in minimal media containing 1.5 g of 15N labeled ammonium chloride (15NH4Cl). In
our hands, initial attempts at expressing 15N-TEV-SrtApneu revealed poor protein yield, which we
speculate was a consequence of inducing expression too late at an OD600 of ~0.8 or above. By
inducing expression in the OD600 range of 0.4-0.6 and incubating for 5 hrs at 37 °C, we were able
to significantly improve protein yields (Figure 18).

Figure 18. An SDS-PAGE analysis of 15N TEV-SrtApneu: (L) Protein molecular weight ladder. *Band
corresponding to 15N TEV-SrtApneu.
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For optimal production of monomeric

15

N-TEV-SrtApneu, we once again found that a

denaturing/refolding protocol was preferred. Thus, as described in section 2.1, cells were first lysed
under denaturing conditions (8 M urea). This was followed by denaturing IMAC purification,
refolding, and non-denaturing IMAC purification. As shown in below, an SDS-PAGE analysis of
the refolded

15

N TEV-SrtApneu following non-denaturing IMAC purification revealed an intense

band between the 20 and 26 kDa molecular weight markers, consistent with the formation of the
desired

15

N-labeled enzyme (Figure 19). This SDS gel displayed a significant monomer

concentration relative to the residual dimer above. The signature presence of bands representing
monomer (bottom) and dimer (top) were also observed on a native-PAGE gel, where the monomer
band intensity was significantly more prominent than all other polypeptides present.

Figure 19. An SDS-PAGE analysis of 15N SrtApneu-TEV refolding IMAC purification scheme (Left):
(1) Protein ladder. (2) Denatured supernatant. (3) Denatured supernatant flow-through. (4) Denaturing
wash flow-through. (5) 1st denaturing elution fraction. (6) 2nd denaturing elution fraction. (7) Rapid
dilution flow-through. (8) Native wash flow-through. (9) 1st native elution fraction. (10) 2nd native
elution fraction. A native-PAGE analysis of 15N SrtApneu-TEV refolding IMAC purification scheme
(Right): (A) Denatured supernatant. (B) Denatured supernatant flow-through. (C) Denaturing wash
flow-through. (D) 1st denaturing elution fraction. (E) 2nd denaturing elution fraction. (F) Rapid dilution
flow-through. (G) Native wash flow-through. (H) 1st native elution fraction. (I) 2nd native elution
fraction.

As a final means of purification, the refolded 15N TEV-SrtApneu was subjected to SEC to
isolate the monomer. The chromatograms from these SEC separations displayed a monomer peak
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significantly larger than dimer (left) and higher molecular weight oligomer (leftmost) peaks.
Fractions encompassing the right-half of the monomer peak were collected to avoid dimer
contamination, then concentrated. These fractions were characterized by ESI-MS to confirm the
identity of the protein, as well as to assess the level of 15N incorporation (Figure 20).

Figure 20. SEC-FPLC traces of IMAC purified 15N SrtApneu-TEV (A) and collected monomeric
fractions (B). A deconvolved mass spectrum (C) of 15N SrtApneu-TEV generated from the corresponding
raw ESI-MS spectrum (D).
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This result indicated an ~84% isotope incorporation for the lighter mass peak, but the
heavier mass peak is implying an impossible percent incorporation. Mass readouts by our ESI-MS
instrument have historically been prone to error when processing biological samples larger than
peptides, so the observed discrepancy in mass was disregarded and the 20,950.5 Da mass was
assumed to resemble ~100% isotope incorporation of SrtApneu-TEV. Although the ESI-MS
readouts didn’t reliably report the extent of SrtApneu-TEV isotopic labelling, we anticipated this
enzyme stock to be sufficient for HSQC NMR.

Figure 21. RP-HPLC analysis of model SML reaction using 15N SrtApneu-TEV at 0-hr (Black), at 1-hr
(Cyan), and after 24-hrs (Marine). (A) Abz-LPATGG-K(Dnp) substrate. (B) Abz-LPATG-NH2OH
product. (C) GG-K(Dnp) excised fragment.

To ensure that the monomeric 15N TEV-SrtApneu preparation was active, it was subjected
to a model sortase-mediated ligation reaction using an Abz-LPATG-GK(Dnp) peptide substrate
and a strong H2NOH nucleophile. The reaction was analyzed via RP-HPLC after an overnight
incubation at room temperature and compared to a control immediately acquired after additional
of the enzyme (i.e. time = 0 h). The UV/Vis chromatogram reported an ~82% conversion of
substrate to modified product, which is in excellent agreement with previous model reactions using
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unlabeled SrtApneu (Figure 21). Based on these results, we were able to determine that
incorporating 15N isotopes into TEV-SrtApneu did not adversely affect its catalytic activity, which
also suggested that its structure was relatively unperturbed.

3.3 2D-HSQC NMR analysis of 15N-labeled TEV-SrtApneu
With a purified sample of monomeric 15N TEV-SrtApneu in hand, we turned our attention
to the acquisition 15N-HSQC spectra. For our initial sample, 15N TEV-SrtApneu was concentrated
to 98 µM, and then combined with D2O (10% v/v), EDTA (0.5 mM) and NaN3 (0.02% w/v) prior
to NMR analysis. The acquired spectrum displayed a number of resonances within the expected
chemical shift range along the 15N axis (100-130 ppm), however the resolution of many signals,
particularly within a central cluster of peaks was poor (Figure 22). While the lack of resolution
made it difficult to discern every signal, we detected ~125 unique resonances, which unfortunately
was well below the more than 200 unique cross peaks we had anticipated for the full-length protein.
Based on this result, we hypothesized that the resolution of 1H-15N couplings could be improved
by modulating the acquisition temperature. Therefore, 15N-HSQC spectra were acquired at 15 and
45 °C. Unfortunately, neither temperature improved the quality of the spectra. Lowering the
temperature reduced the resolution of peaks centered within the cluster, and raising the temperature
caused the enzyme to precipitate.
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Figure 22. 2D HSQC NMR acquisitions of 15N SrtApneu-TEV (98 µM) at RT (Red) and 15 °C (Blue).
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Next, we attempted to improve the resolution of the 15N-HSQC spectrum by adjusting the
enzyme concentration. This idea was based on the possibility that the enzyme may exist in solution
as an equilibrium between monomeric and higher order aggregates, and therefore adjusting the
concentration may alter the ratio between those species. First, we prepared a 5x diluted sample
derived from our original 98 µM enzyme stock. In this case, the NMR was unable to detect any
1

H-15N signatures, likely due to the lower overall concentration and corresponding reduction in

signal-to-noise. We then proceeded to generate a more concentrated (225 µM) stock of 15N TEVSrtApneu and were encouraged to see a 15N-HSQC spectrum with smooth and well-defined contours
outlining the perimeter of peaks (Figure 23). However, peaks in the center of the cluster remained
largely undefined, and therefore unsuitable for resonance assignment and structure determination.

Figure 23. 2D HSQC NMR acquisition of 15N SrtApneu-TEV (225 µM) at RT.

36

Given that increasing the enzyme concentration did not entirely alleviate the resolution
issues with our spectrum, we speculated that the poorly defined central cluster of peaks may be
the result of conformationally labile portions of the enzyme, for example at the N-terminus where
a TEV cleavage site and His6 tag were present. To begin to probe this, we first generated a 15Nlabeled version of SrtApneu lacking the TEV cleavage site, but retaining the His6 tag. This protein
was prepared and characterized following the same protocol for 15N TEV-SrtApneu. A concentrated
stock (171 µM) of SrtApneu without a TEV cleavage site was generated, and an NMR sample was
prepared with standard conditions.

Figure 24. 2D HSQC NMR acquisition of 15N SrtApneu (171 µM) at RT.

The acquired

15

N-HSQC spectrum did yield some improvement and unique ~175 peaks

were observed, including the appearance of new peaks around the exterior of the peak cluster a
more resolved interior peak cluster as compared to 15N TEV-SrtApneu (Figure 24). While this slight
improvement in resolution was encouraging, this sample SrtApneu lacking a TEV cleavage site still
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did not provide sufficient resolution for determining the structure of SrtApneu as there remained a
significant margin of error for discerning individual peaks within the central cluster.

As a final means of probing the impact of the enzyme N-terminus, we also used TEV
protease to generate a sample of 15N SrtApneu (80.5 µM) lacking both the TEV cleavage site and
the His6 tag. While TEV cleavage was successful, as indicated by ESI-MS, the resulting the 15NHSQC spectrum did not provide significant improvements in signal resolution (Figure 25).

Figure 25. 2D HSQC NMR acquisition of TEV-cleaved 15N SrtApneu (80.5 µM) at RT.

Overall, while we have successfully generated a sample of

15

N-labeled enzyme that is

active and appears to be monomeric, we have yet to acquire two-dimensional data that is suitable
for full resonance assignment and subsequent structure determination. The reasons for this are not
entirely clear, however we speculate that portions of SrtApneu may be conformationally labile in
solution, leading to poorly defined regions in the
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15

N-HSQC spectrum. Consistent with this

interpretation, we note that the central cluster of poorly defined peaks falls within the range of
110-125 ppm on the 15N axis, which is where disordered regions of proteins are often observed.
We also note that regions of disorder have been observed in sortase A homologs in other
organisms, for example in the case of sortase A from S. aureus where binding of the LPXTG
substrate appears to induce a disorder-to-order transition with loops flanking the enzyme active
site.

Chapter 4 – Progress Toward Preparation of Substrate-docked derivatives of
SrtApneu
4.1 – Design and Synthesis of ketomethylene isosteres
In addition to determining the structure of SrtApneu in the absence of substrate, we have
also been pursuing strategies for generating enzyme bound to substrate mimetics in order to clearly
delineate the interactions between the sorting motif and the enzyme active site. As described in
Chapter 1, structures of sortase A from S. aureus and B. anthracis have been reported in which the
enzymes are bound to a substrate analog that mimics the acyl enzyme intermediate. This approach
has provided excellent insight into the recognition of the first four residues of the LPXTG sorting
motif, however it fails to clearly identify contacts that dictate substrate selectivity involving the 5th
position (often G) of the sorting signal. To address this issue, previous work in the Antos lab sought
to replace the scissile amide linkage between the 4th and 5th position residues with a non-cleavable
carbon-carbon bond. Specifically, a ketomethylene dipeptide isostere (5-aminolevulinic) was
incorporated into a peptide substrate in place of the native threonine and glycine residues (Figure
26).
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Figure 26. Structural comparison of a model LPATG substrate to a 1st generation inhibitor substrate.
The 4th and 5th position residues of the model substrate have been replaced with a ketomethylene linked
diglycine.

Preliminary evaluation showed that this substrate was not cleaved by SrtApneu, and
additionally it was able to inhibit enzyme activity was added to a model in vitro reaction.70 While
encouraging, it was recognized that 5-aminolevulinic was not the optimal diketomethylene
building block for this approach as it mimicked a diglycine dipeptide structure without any of the
relevant amino acid side chains.

Figure 27. Structural comparison of 1st generation and 2nd generation inhibitor substrates. The 4th
position residue of the 1st generation substrate has been replaced with an alanine to serve as an improved
mimic of the preferential 4th position threonine.
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To address this limitation, we sought to develop a synthetic approach for preparing
diketomethylene analogs that included substituents in positions that mirrored natural amino acids.
Moreover, we wanted to prepare building that would be compatible with standard solid-phase
synthesis techniques. To that end, we designed ketomethylene analog A[keto]G as an initial
synthetic target, which would mimic an alanine-glycine dipeptide rather than a glycine-glycine
dipeptide (Figure 27).

Figure 28. Overview of the proposed synthetic scheme based on procedures from Budnjo et al. and
Mathieu et al. using a Boc-protected amino acid starting material.

We adopted a synthetic strategy by Budnjo et al.1 and Mathieu et al.2 in order to produce
analog 4 (Figure 28). The synthesis began by combining excess lithium enolate of t-butyl acetate
and carbonyldiimidazole (CDI)-activated Boc-Ala-OH in the presence of a 4-dimethylaminopyridine (DMAP) catalyst. The resulting Boc-ketoester (1) was isolated in 70% yield, and then
used as a nucleophile in a stereospecific substitution of a triflate (2) derived from t-butyl-2hydroxyacetate. Triflate (2) was prepared separately using t-butyl-2-hydroxyacetate, triflic
anhydride and 2,6-lutidine. Deprotonation of the Boc-ketoester by excess NaH, followed by dropwise addition of 2 resulted in the production of Boc-ketomethylene (3) (41% yield). The identity
of Boc-ketomethylene (3) was confirmed by proton nuclear magnetic resonance spectroscopy (1H41

NMR), as well as low resolution LC-ESI-MS which reported a molecular weight consistent with
the Na2+-adduct of the Boc-ketomethylene. Subsequent exposure to trifluoroacetic acid (TFA)
provided a means to remove t-butyl ester and Boc protecting groups, which was followed by an
in-situ decarboxylation to generate an unprotected precursor. This intermediate was not isolated
and

was

immediately

reprotected

using

Fmoc-OSu

in

the

presence

of

excess

diisopropylethylamine (DIPEA). While the formation of the target compound (4) was confirmed
via low resolution LC-ESI-MS and 1H-NMR, overall yields were very poor (<7%) and indicated
the need for further synthesis optimization.
Table 4. Summary of Boc-Ketomethylene reaction optimization results.

Optimization of the reaction cascade began by focusing on the synthesis of Bocketomethylene (Table 4). Alternate bases (KOtBu or LiHMDS) were used in place of NaH, and
the replacement of THF with DMF was also attempted. Unfortunately, all variations produced
lower yields than the original reaction conditions. We then tried to replace the sensitive t-butyl-2hydroxyacetate triflate (2) with the less reactive and commercially available t-butyl bromoacetate,
and were encouraged to observe significant improvements in Boc-ketomethylene yield.
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Next, we sought to investigate the Fmoc reprotection step used to generate the final
ketomethylene product (Figure 29). Using the Fmoc protection of 5-aminolevulinic acid as a
model, we found that replacement of DIPEA with sodium carbonate (Na2CO3) and the use of 0.96
eq of Fmoc-OSu improved gave acceptable reaction yields.

Figure 29. Reaction scheme for synthesizing a G[keto]G building block for SPPS.

Unfortunately, use of these conditions to prepare the final ketomethylene target (A[keto]G)
did not significantly increase the amounts we were able to recover, as purification via column
chromatography consistently failed to produce entirely pure product, despite variations in eluent,
the inclusion of 0.1% acetic acid in the mobile phase, or the use of dry loading techniques.

Figure 30. Synthesis of 2nd generation ketomethylene substrate analog using the A(keto)G building
block (highlighted) to install a non-cleavable linkage between 4th and 5th residues.

While the synthesis of 4 remained problematic, we felt that some initial proof-of-concept
work on its incorporation into a substrate analog were warranted to establish whether any
additional synthesis optimization would be worthwhile. Thus, a large-scale SPPS preparation of 4
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beginning with 300 mg of 3 was performed, resulting in the recovery of 200 mg of the final Fmocprotected product (<73% yield), which was confirmed by both 1H-NMR and low-resolution LCESI-MS. This provided enough material for use in solid-phase synthesis, which was initiated using
Rink amide resin and a standard Fmoc-based approach (Figure 30). Unfortunately, following
cleavage of the crude peptide from the resin, no evidence for the formation of the desired substrate
analog would be detected by LC-ESI-MS or RP-HPLC. Overall, this prompted us to abandon this
approach and redirect efforts to the alternate substrate analog design described below.

4.2 – Third generation design using disulfide linked analog
Having struggled with synthesis of a ketomethylene-containing substrate analog, we
developed an alternate strategy for generating a substrate bound analog of SrtApneu that relied
entirely on standard amino acid residues and standard solid-phase synthetic techniques. This
strategy involves replacing the standard LPATG motif with a derivative containing cysteine (C) in
place of the native threonine (T) (Figure 31).

Figure 31. Structural comparison of a model LPATG substrate to a 3rd generation inhibitor substrate.
The 4th and 5th position residues of the model substrate have been replaced with cysteine and glycine,
respectively.
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Subsequently, disulfide bond formation with the enzyme active site would be used to
anchor the peptide. While this approach would yield a somewhat artificial enzyme analog that does
not exactly reproduce all the contacts between enzyme and substrate, this approach has been
reported in the context sortase A from S. aureus and shown to provide a means for identifying
enzyme residues by solution NMR that are likely to be involved in substrate recognition.
Additionally, we hypothesized that the presence of a substrate analog could serve to stabilize the
enzyme structure, and alleviate the disorder observed in

15

N-HSQC spectra of the free enzyme

described in Chapter 3.

Work on this approach began by synthesizing a Bz-GLPACGG peptide using standard solid phase
synthesis. The peptide was purified by RP-HPLC, and its identity was confirmed by LC-ESI-MS
(Figure 32).. With the peptide in hand, we then activated the cysteine by conversion to a mixed
disulfide using 2,2’-dithiopyridine. Quantitative formation of the mixed disulfide was clearly
evident after 30 minutes as determined by LC-ESI-MS, and the product was subsequently isolated
by RP-HPLC. Test reactions were then performed in which the thiopyridyl modified peptide was
combined TEV-SrtApneu in various ratios (2-50 equivalents) at room temperature. Using LC-ESIMS, it was observed that an excess of peptide (50 equiv.) was ideal for rapid and quantitative
formation of the desired enzyme adduct (Figure 33).
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Figure 32. Shown above is a reaction for generating a Bz-GLPACGG peptide appended to a
thiopyridine group. RP-HPLC/LC-ESI-MS analysis for determining the purity and molecular weight of
Bz-GLPACGG starting material (top) and modified peptide product (bottom).
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Figure 33. Shown above is a reaction for appending Bz-GLPACGG to the active-site cysteine of
SrtApneu. Deconvolved mass spectra of unmodified SrtApneu (A) and substrate bound enzyme (B).
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Chapter 5 – Conclusion and Future Directions
The results reported in this thesis describe our progress toward characterizing the structure
of SrtApneu bound to a substrate. Chapter 2 detailed the utilization of x-ray crystallography to
determine the unbound structure of SrtApneu, which began by employing methods of reducing the
assembled forms of the enzyme by denaturing IMAC purification and isolating the monomer by
SE-FPLC. Spin concentrated monomeric preparations were subjected to INDEX and PEG/Ion2
screening kits, which revealed several crystal hits featuring Bis-Tris as a component of each
condition. Therefore, we anticipated that the presence of Bis-Tris favored crystal formation and
endeavored toward optimizing the screening conditions in an effort to grow diffractable crystals.

Among all of the optimization trials we had attempted, crystal growth appeared to be
significantly dependent on pH and PEG 3350 concentration. In particular, our top candidates were
grown in conditions with a pH ranging from 4.5-5.5, and concentrations of PEG 3350 between 2426%. Other optimization trials we had conducted devaited Bis-Tris, or tuning salt, concentrations
as well as alternative enzyme to mother liquor hanging drop compositions. We had even tried
exploring chloride-containing conditions not included within the preliminary screening kits, but
we were still unable to find an optimal crystal condition. Regardless, we sought to diffract the
suboptimal crystals generated thus far, however, we were unable to glean any structural
information.

In consideration of the theory guiding crystal packing, even the slightest presence of
dimeric SrtApneu may have significantly perturbed unit cell assembly of monomers. This may
provide a rationale for our challenges with protein crystallization, where the enzyme stock may be
more at fault than the conditions we had employed. To our credit, we prepared the sample to the
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best of our ability considering our experiences with dimeric SrtA persisting regardless of
denaturing and reducing preparations as well as the poor resolution afforded by our size exclusion
column. Taken together, we were unable to solve the structure of unbound SrtApneu via x-ray
crystallography in a timely manner, which propelled our efforts toward utilizing solution NMR as
described in Chapter 3.

Chapter 3 detailed our efforts toward characterizing the structure of substrate-bound
SrtApneu by solution NMR, which began by utilizing standard IMAC purification and SEC isolation
of monomeric SrtApneu-TEV. We opted to express a SrtApneu construct with a TEV cleavage site
prior to the N-terminal His6 tag in the anticipation that its presence may perturb native folding.
Initially, we sought to determine if SrtApneu-TEV is conformationally stable over the course of
several days, as we were concerned for the integrity of enzyme stocks moving forward to numerous
lengthy HSQC acquisitions. We were confident that SrtApneu-TEV remained stable based on the
spectra consistency observed in the amide region reported by several 1D 1H-NMR acquisitions.

Next, we redirected our efforts toward expressing our construct in minimal media to
isotopically label SrtApneu-TEV with 15N for prospective HSQC NMR. The overall success of the
isotopically labelled protein expression was largely dependent on the OD600 (0.4-0.6) of the
minimal media prior to inducing expression with IPTG, and the period of expression (5 hrs). These
efforts generated a 98 µM stock of 15N SrtApneu-TEV, where HSQC acquisition revealed a cluster
of poorly resolved peaks containing approximately 125 peaks. LC-ESI-MS of 15N SrtApneu-TEV
demonstrated a high degree of isotope incorporation, which was inconsistent with the number of
couplings reported by our HSQC spectrum. Based on the advice of our NMR collaborator, we
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subjected the 98 µM enzyme stock to 15 °C and 45 °C during acquisition to observe improvements
in the resolution. Unfortunately, lowering the temperature did not enhance the spectral resolution,
and increasing the temperature caused the enzyme to precipitate out of solution.

Sequential HSQC acquisitions of a stock with a significantly higher concentration resulted
in refinement of peaks confined in the perimeter of the cluster, however, the cluster interior
remained largely undefined and the number of observable couplings was unchanged. We suspected
that insertion of the TEV recognition sequence may have compromised the folding dynamics of
the enzyme. Accordingly, we expressed isotopically labeled a SrtApneu construct lacking a TEVsite. HSQC acquisition of SrtApneu displayed the appearance of 50 new peaks in addition to those
observed previously. Although promising, the removal of the TEV-site did not facilitate detection
of all 1H-15N couplings implied by preliminary MS data. Furthermore, HSQC acquisition of a TEV
cleaved 15N SrtApneu-TEV expression construct provided no indication of improvement.

Taken together, the evidence suggested that neither His6 tag nor TEV-site was the direct
cause of our resolution dilemma. Rather, we hypothesized the possibility that active unbound
SrtApneu could exist as multiple transient conformations compared to the stable substrate-bound
acyl-enzyme intermediate. We began to justify our complications with enzyme crystallization and
poor HSQC resolution based on the premise that the in vitro behavior of the active enzyme is more
dynamic than we had initially anticipated. As discussed in Chapter 4, we sought to design a noncleavable peptide analog to dock in the active site in order to stabilize the acyl-enzyme
conformation and constrain the movement of nuclei during HSQC acquisition for improved
resolution.
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Chapter 4 encompassed the synthesis of 2nd and 3rd generation peptide inhibitors for their
use towards determining the structure of substrate-bound SrtApneu-TEV via solution NMR.
Previous efforts had demonstrated a reasonable capacity for 1st generation LPA[G(keto)G]G
inhibitors to compromise the activity of SrtApneu in the presence of a model substrate and
nucleophile. However, the suboptimal efficacy of this proof of concept inhibitor was reflective of
missing active site contacts with canonical Thr and Ala residues in the 4th and 5th positions of the
substrate, respectively. Attempts to synthesize the 2nd generation LPA[A(keto)G]G peptide analog
were founded on prior efforts toward generating a ketomethylene-linked dipeptide isostere
mimicking Ala and Gly, which more closely resembled a model LPATAG substrate upon SPPS
incorporation.

The original synthesis cascade of an SPPS amenable Fmoc protected [A(keto)G] construct
was burdened by a very poor overall yield. The most notable alteration in the procedure that led to
improved yields involved the substitution of t-Bu-2-hydroxyacetate triflate for t-Bu-bromoacetate,
which also abrogated the necessity for triflate preparation prior to Boc-ketoester synthesis.
Numerous rounds of optimization afforded a sizeable stockpile of Fmoc-[A(keto)G], but we were
unable to successfully incorporate it into a peptide via SPPS. Prior to SPPS, we had confirmed the
identity of Fmoc-[A(keto)G] by 1H-NMR and LC-ESI-MS. In theory, Fmoc-[A(keto)G] should be
behave similarly to our commercially acquired SPPS coupling agents and we’ve yet to develop an
explanation for our observations.
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Having struggled with the synthesis of the 2nd generation peptide analog, we developed an
alternative 3rd generation substrate design based on standard amino acid residues and standard
solid-phase synthetic techniques. This strategy involved replacing the 4th position threonine of a
model LPATG substrate with cysteine, where the enzyme active site cysteine was anticipated to
form a disulfide bridge upon substrate docking. Therefore, characterization of substrate-bound
SrtApneu-TEV would demonstrate key binding interactions with the 5th position residue, beyond
the contacts established by the first four residues reported by Suree et al. (PDB ID: 2KID). A BzGLPACGG-NH2 peptide prepared with a thiopyridine leaving group in the 4th position cysteine
was successfully synthesized and demonstrated the capacity to covalently bind to SrtApneu using
excess substrate leaving miniscule traces of unbound enzyme.

Considering that the 3rd generation peptide was capable binding to SrtApneu, future efforts
should be directed toward observing if the peptide is accepted by

15

N SrtApneu-TEV. Upon

confirming the identity of substrate-bound enzyme via LC-ESI-MS, subsequent steps include
isolating the substrate-enzyme complex, determining the lifetime, followed by HSQC acquisition.
If the appearance of highly resolved (>200) peaks is observed, then our hypothesis pointing blame
on enzyme mobility for compromising peak detection and resolution would likely be correct.
Lastly, a 3D NMR would be acquired to begin assigning peaks to individual amino acids
composing the enzyme primary sequence. Based on this analysis, we may finally assess active site
residues prompting key interactions with each position along the substrate.

Regardless of the shortcomings discussed in this thesis, we’ve been able to establish a
foundation for unveiling aspects of SrtApneu specificity and structural characterization that are not
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currently reported in literature. Pursuance of determining the structure of substrate-bound SrtApneu
with our 3rd generation peptide analog may reveal unpublished active site interactions with the 5th
position residue. In light of this, we may begin to assemble a complete understanding of SrtA
substrate specificity based on published interactions with the first four substrate residues and our
newly reported 5th position contacts. As we continue to develop a structure-function relationship
for SrtA homologs, we can begin to utilize their unique properties to expand the scope of sortase
mediated ligation.

Chapter 6 – Experimental
6.1 Expression of SrtApneu
The following construct was obtained via commercial gene synthesis from DNA 2.0.
Full sequence of Δ80SrtApneu:
MESSHHHHHHAVLTSQWDAQKLPVIGGIAIPELEMNLPIFKGLDNVNLFYGAGTMKRE
QVMGEGNYSLASHHIFGVDNANKMLFSPLDNAKNGMKIYLTDKNKVYTYEIREVKRVT
PDRVDEVDDRDGVNEITLVTCEDLAATERIIVKGDLKETKDYSQTSDEILTAFNQPYKQF
Y

The following construct was obtained via commercial gene synthesis from ATUM.
Full sequence of Δ80SrtApneu-TEV:
MHHHHHHENLYFQGAVLTSQWDAQKLPVIGGIAIPELEMNLPIFKGLDNVNLFYGAGT
MKREQVMGEGNYSLASHHIFGVDNANKMLFSPLDNAKNGMKIYLTDKNKVYTYEIRE
VKRVTPDRVDEVDDRDGVNEITLVTCEDLAATERIIVKGDLKETKDYSQTSDEILTAFNQ
PYKQFY
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Non-Isotopically Labelled SrtApneu Expression: A 50 uL aliquot of BL21(DE3) cells in 50%
glycerol containing the plasmid for SrtApneu was added to 50 mL of LB broth containing 100
µg/mL ampicillin and incubated with shaking at 37 °C overnight. Roughly 25 mL of culture was
then added per 1 L of LB broth containing 100 µg/mL ampicillin to initiate largescale growth. This
culture was allowed to grow to an OD600 reading of 0.7-0.8 at 37 °C in a shaking incubator (210
RPM) before induction with 1 mL of 1 M IPTG. Cells remained at 37 °C with shaking for at least
three hours to express SrtApneu, and were then isolated by centrifugation at 6000 RPM. Pelleted
cells were subsequently stored at -80 °C.

Minimal Media Isotopically Labeled SrtApneu Expression: A 50 uL aliquot of BL21(DE3) cells in
50% glycerol containing the plasmid for SrtApneu-TEV-His6 was added per 50 mL of LB broth
containing 100 µg/mL kanamycin to initiate a 100 mL seed culture growth, which was incubated
with shaking (210 RPM) at 37 °C overnight. Roughly 25 mL of culture was added per 1 L of LB
broth containing 100 µg/mL kanamycin to initiate a large scale 4 L growth. This culture was
allowed to grow to an OD600 reading of 0.4-0.5 at 37 °C in a shaking incubator (210 RPM), and
cells were isolated by centrifugation at 4000xg for 20 minutes at 4 °C. Pelleted cells were
resuspended in 500 mL of a 1 L salt wash (22 mM Na2PO4, 22 mM KH2PO4, 8.6 mM NaCl, 1 mM
MgCl2, 2.5 μM B1 Vitamin, 100 μM CaCl2, 100 ug/mL kanamycin) solution, and cells were
isolated by centrifugation at 4000xg for 20 minutes at 4 °C. Pelleted cells were resuspended in 500
mL of minimal growth media (22 mM Na2PO4, 22 mM KH2PO4, 8.6 mM NaCl, 1 mM MgCl2, 2.5
μM B1 Vitamin, 100 μM CaCl2, 100 ug/mL kanamycin, 25 mM D-glucose, 27.5 mM 15N-NH4Cl),
and the culture was allowed to grow to an OD600 reading of 0.6 at 37 °C in a shaking incubator
(210 RPM) before induction with 1 mL of 1 M IPTG. Cells remained at 37 °C with shaking for
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five hours to express 15N SrtApneu, and were then isolated by centrifugation at 5000 RPM for 20
minutes at 4 °C. Pelleted cells were subsequently stored at -80 °C.

Native purification: Frozen cell pellets were resuspended in 30 mL denaturing lysis buffer (50
mM Tris pH 7.5, 150 mM NaCl, 0.5 mM EDTA). The resuspended cells were sonicated for two
30 second intervals at 50% power output and the lysate was clarified by centrifugation at 17,500
RPM (Thermo Scientific Fiberlite F20-12x50 LEX rotor). This clarified lysate was added to 5 mL
of His-Bind resin (Thermo-Fisher) column pre-equilibrated in denaturing wash buffer (50 mM Tris
pH 7.5, 150 mM NaCl, 20 mM imidazole). Bound protein was washed with 10 column volumes
of wash buffer and then eluted in two 1 column volume portions of denaturing elution buffer (50
mM Tris pH 7.5, 150 mM NaCl, 300 mM imidazole). Collected fractions were analyzed by native
and SDS-PAGE. SrtApneu monomer was further purified on an NGC FPLC system (Bio-Rad) by
size-exclusion chromatography using an Enrich SEC 70 column (Bio-Rad) with running buffer
(50 mM Tris pH 7.5, 150 mM NaCl) or a HiPrep 16/60 Sephacryl 200-HR column as the eluent at
either 0.2 mL/min or 0.5 mL/min. Monomeric protein fractions were pooled, and if necessary,
concentrated using centrifugal concentrators (10 KDa MW cutoff). Samples were stored at 4 °C
for temporary storage or -20 °C for long term storage.

Refolding Purification: Frozen cell pellets were resuspended in 30 mL denaturing lysis buffer (50
mM Tris pH 7.5, 150 mM NaCl, 1 mM TCEP, 0.5 mM EDTA, 8 M urea). The resuspended cells
were sonicated for two 30 second intervals at 50% power output and the lysate was clarified by
centrifugation at 17,500 RPM. This clarified lysate was added to 5 mL of His-Bind resin (ThermoFisher) column pre-equilibrated in denaturing wash buffer (50 mM Tris pH 7.5, 150 mM NaCl, 1
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mM TCEP, 20 mM imidazole, 8 M urea). Bound protein was washed with 10 column volumes of
wash buffer and then eluted in two 1 column volume portions of denaturing elution buffer (50 mM
Tris pH 7.5, 150 mM NaCl, 1 mM TCEP, 300 mM imidazole, 8 M urea). The first eluted fraction
was then rapidly diluted (100x) by addition to dilution buffer (50 mM Tris pH 7.5, 150 mM NaCl,
1 mM TCEP). This material was then recirculated through a 5 mL Ni-NTA column equilibrated
in native wash buffer (50 mM Tris pH 7.5, 150 mM NaCl, 1 mM TCEP, 20 mM imidazole). Bound
protein was further washed with 10 column volumes of native wash buffer, then eluted in two 1
column volume aliquots of native elution buffer (50 mM Tris pH 7.5, 150 mM NaCl, 1 mM TCEP,
300 mM imidazole). Collected fractions were analyzed by native and SDS-PAGE. SrtApneu
monomer was further purified on an NGC FPLC system (Bio-Rad) by size-exclusion
chromatography using an Enrich SEC 70 column (Bio-Rad) or a HiPrep 16/60 Sephacryl 200-HR
column with running buffer (50 mM Tris pH 7.5, 150 mM NaCl, 1 mM TCEP) as the eluent at
either 0.2 mL/min or 0.5 mL/min. Monomeric protein fractions were pooled, and if necessary,
concentrated using centrifugal concentrators (10 KDa MW cutoff). Samples were stored at 4 °C
for temporary storage or -20 °C for long term storage.

Evaluation of protein concentration. UV/Vis spectroscopy for determining concentrations of the
prepared samples was performed on a NanodropTM ND1000 spectrophotometer (Thermo
Scientific) at 280 nm using 17,420 M-1 cm-1 (SrtApneu) or 18,910 M-1 cm-1 (SrtApneu-TEV) as the
estimated molar extinction coefficient from analysis of the protein sequence by ExPASy
ProtParam.
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Protein LC-ESI-MS Analysis. Liquid chromatography electrospray ionization mass spectrometry
(LC-ESI-MS) was performed using a Dionex Ultimate 3000 HPLC system (Thermo Scientific)
connected to an expressionL high performance compact mass spectrometer (Advion, Inc.) through
analytical scale separations using a Phenomenex Kinetex 2.6 µm, 100 Å C4 column (2.0 x 100
mm) with Method B. Data analysis was conducted by Advion Data Express software version 3.0.
Mass spectrum deconvolution was achieved through a max entropy algorithm to determine
uncharged masses of samples.

6.2 Protein Crystal Preparations & Diffraction
Crystallization of SrtApneu. Efforts to produce crystals suitable for x-ray diffraction were grown via
hanging drop vapor diffusion. All hanging drop loadings were composed of 1:1 mother liquor to
enzyme (2 μL drop), unless stated otherwise, using a 6 mg/mL SrtApneu stock. PEG/ION2 and
INDEX screening kits were utilized, and crystal formation was observed under the following
conditions: 0.2 M sodium acetate pH 7.0 20% w/v PEG 3350 4 °C (C1), 0.2 M sodium formate
pH 7.0 20% w/v PEG 3350 4 °C (C2), 0.2 M sodium malonate pH 6.0 20% w/v PEG 3350 4°C
(C3), 0.1 M Bis-Tris pH 5.5 25% w/v PEG 3350 21 °C (C4), 0.1 M Bis-Tris pH 5.5 0.2 M Sodium
Chloride 25% PEG 3350 21 °C (C5), 0.1 M Bis-Tris pH 5.5 0.2 M Ammonium Acetate 25% w/v
PEG 3350 21 °C(C6), 0.1 M Bis-Tris pH 5.5 0.2 M Magnesium Chloride hexahydrate 25% w/v
PEG 3350 21 °C (C7). Room temperature screening conditions (C4-7) were modified by
optimizing pH, PEG 3350 and salt concentrations, as well as mother liquor:enzyme drop loading
ratio. Optimization efforts around the C4-7 conditions varied pH (pH 4.5-7.5 in steps of 1 pH, pH
4.5-5.5 in steps of 0.2 pH) and PEG concentration (18-28% w/v in steps of 2% w/v). Optimization
of C4 (pH 4.5/5.5) varied Bis-Tris concentrations (0.05-0.30 M in steps of 0.05 M), and
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optimization of C5-7 (pH 4.5/5.5) varied concentrations of the salts in addition to 0.1 M Bis-Tris
(0.05-0.2 M in steps of 0.05 M, and 0.2-0.4 M in steps of 0.1 M), where 1:1 (2 uL drop) and 2:1
(3 uL drop) mother liquor to enzyme ratios were used for C4-7. Furthermore, conditions C4-7 were
optimized by varying PEG 3350 concentration (20-30% w/v in steps of 2% w/v) and mother liquor
to enzyme ratio (1:1, 1:2, 2:1, 2:2, 1:3, and 3:1). Observed crystal conditions not evaluated in the
preliminary screening, yet were anticipated to induce crystal growth, included: 0.1 M Bis-Tris pH
5.5 0.2 M Potassium Chloride 25% w/v PEG 3350 21 °C (C8), 0.1 M Bis-Tris pH 5.5 0.2 M
Ammonium Chloride 25% w/v PEG 3350 21 °C (C9), 0.1 M Bis-Tris pH 5.5 0.2 M Calcium
Chloride 25% w/v PEG 3350 21 °C (C10). Crystal screening of C8-10 (pH 4.5/5.5) involved
varying concentrations of the salts in addition to 0.1 M Bis-Tris (0.05-0.2 M in steps of 0.05 M,
and 0.2-0.4 M in steps of 0.1 M).

X-ray Diffraction: Crystals from the following conditions were analyzed via x-ray diffraction: 0.05
M Bis-Tris pH 5.5 25% w/v PEG 3350 21 °C; 0.25 M Bis-Tris pH 5.5 25% w/v PEG 3350 21 °C,
0.05 M Bis-Tris pH 5.5 0.05 M Ammonium Acetate 25% w/v PEG 3350 21 °C; 0.1 M Bis-Tris
pH 5.5 0.15 M Magnesium Chloride hexahydrate 25% w/v PEG 3350 21 °C; 0.1 M Bis-Tris pH
5.5 0.05 M Sodium Chloride 25% PEG 3350 21 °C. Crystals looped from these conditions were
cryoprotected by washing each crystal with respective crystal inducing conditions with 30% v/v
glycerol, followed by immediate flash freezing in liquid nitrogen. All x-ray diffraction data was
collected on a Rigaku XtaLAB PRO diffractometer.
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6.3 NMR sample Preparation & Acquisition
NMR samples contained 50–300 μM of SrtApneu-TEV-His6 or SrtApneu-His6 (unlabeled as well as
labeled with 15N), which were all prepared under NMR conditions (10% v/v D2O, 0.5 mM EDTA,
0.02% w/v NaN3). NMR spectra were collected with a Brüker Avance spectrometer at 500 MHz
for both 1D 1H and 2D HSQC FID processing, and figure generation was done using Mestrelab
MestReNova software version 10.0.2-15465.

6.4 Synthesis of ketomethylene isosteres
All chemicals were obtained from commercial sources and were used without further purification.
NMR spectra were collected with a Brüker Avance spectrometer at 500 MHz for 1H. FID
processing and figure generation was done using Mestrelab MestReNova software version 10.0.215465. All reactions were performed in flame-dried glassware under argon atmosphere. HPLC
purification and analysis was performed using a Dionex Ultimate 3000 HPLC system. LC-ESIMS was performed with a Dionex Ultimate 3000 HPLC system connected in line to an expressionL
high performance compact mass spectrometer (Advion, Inc.). Analytical separations for MS
analysis of synthetic products were achieved with a Phenomenex Kinetex 2.6 µm, 100 Å C18
column (2.1 x 100 mm) with the following method: MeCN (0.1% formic acid) / 95% H2O, 5%
MeCN (0.1% formic acid) mobile phase. Flow rate = 0.3 mL/min. Gradient = 5% MeCN (0.0-0.5
min), 5% MeCN to 90% MeCN (0.5-5.0 min), hold 90% MeCN (5.0-7.0 min), 90% MeCN to 10%
MeCN (7.0-7.1 min), re-equilibrate to 10% MeCN (7.1-10.0 min).

tert-butyl 2-(((Trifluoromethyl)sulfonyl)oxy)acetate (1). A solution of t-butyl 2-hydroxyacetate
(0.66 g, 5.0 mmol) in dry DCM (20 mL) was combined with 2,6-lutidine (0.87 mL, 5.0 mmol).
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The mixture was cooled to 0 °C and triflic anhydride (1.18 mL, 5.0 mmol) was added dropwise
over 70 minutes, during which time the color changed to light red then orange. After stirring for 1
hour at 0 °C, the reaction mixture was diluted with n-hexane (100 mL), washed with 1:3 1 M
HCl/sat. NaCl (3x, 50 mL), and dried over MgSO4. The extract was concentrated by rotary
evaporation and dried under vacuum to afford the product as a red/orange oil which was used
without further purification (0.71 g, 41% yield). 1H NMR (500 MHz, CDCl3): δ 4.80 (s, 2H), 1.54
(s, 9H).

tert-butyl (S)-4-((tert-butoxycarbonyl)amino)-3-oxopentanoate (2). Boc-Ala-OH (1.32 g, 7.0
mmol) was dissolved in dry THF (20 mL) and then treated with CDI (1.08 g, 7.7 mmol), which
was added in three portions while stirring, resulting in bubble formation. Within five minutes of
CDI addition, DMAP (26 mg, 0.21 mmol) was added to the reaction mixture. This was left to stir
for one hour. In a separate flask, t-butyl acetate (4.1 mL, 28.7 mmol) was added dropwise to 1 M
LiHMDS (28 mL, 28 mmol) in THF (28 mL) at -78 °C under stirring over the course of ~10
minutes. This reaction was left to stir for 20 min at -78 °C, and then removed from cooling and
stirred at room temperature for an additional 10 minutes. The enolate solution was then again
cooled to -78 °C and stirred for 20 additional minutes, followed by the dropwise addition of the
CDI-activated Boc-Ala-OH over 10 minutes. The combined reaction was allowed to stir for 1.5
hrs at -78 °C before being quenched with 10% w/v citric acid (50 mL). The mixture was extracted
with ethyl acetate (2x, 30 mL), washed with sat. NaHCO3 (30 mL) and sat. NaCl (3x, 30 mL), and
then dried over MgSO4. After concentration by rotary evaporation, the crude product was purified
by flash column chromatography (1:3 EtOAc/n-hexane) yielding the product as a white solid (1.38
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g, 70% yield). 1H NMR (500 MHz, CDCl3): δ 5.15 (m, 1H), 4.38 (m, 1H), 3.46 (q, J = 15.6 Hz,
2H), 1.46 (s, 9H), 1.44 (s, 9H), 1.36 (d, J = 7.2, 3H).

General procedure for synthesis of di-tert-butyl 2-((tert-butoxycarbonyl)-L-alanyl)succinate (3).
Boc-Ala ketoester (2) (0.50 g, 1.74 mmol) was dissolved in dry THF (10 mL) and added dropwise
to a stirred suspension of NaH (60% in mineral oil, 0.126 g, 3.2 mmol) in dry THF (10 mL) at -5
°C. This mixture was allowed to stir for 20 min, after which t-Bu-bromoacetate (390 µL, 2.64
mmol) was added at -5 °C. The reaction was allowed to stir overnight at room temperature before
being quenched with 10% w/v citric acid (15 mL). The quenched reaction was extracted with
EtOAc (3x, 30 mL) washed with sat. NaCl (90 mL) and dried over MgSO4 before being
concentrated via rotary evaporation to yield a yellow oil. This residue was purified by flash column
chromatography with 1:5 EtOAc/hexane and the desired product fractions identified by TLC were
pooled, and concentrated by rotary evaporation (0.55 g, 79% yield).1H NMR (500 MHz, CDCl3)
δ 5.24 (dd, J = 13.6, 5.6 Hz, 1H), 4.68-4.44 (m, 1H), 4.11 (ddd, J = 16.9, 8.2, 6.5 Hz, 1H), 2.882.68 (m, 2H), 1.50-1.37 (m, 27H), 1.37-1.33 (m, 3H).

(S)-5-((((9H-fluoren-9-yl)methoxy)carbonyl)-amino)-4-oxohexanoic acid (4). Compound 3 (0.3
g, 0.747 mmol) was solvated in 10% TFA/DCM (25 mL) and allowed to stir overnight at room
temperature. After concentrating the resulting mixture by rotary evaporation, the residue was
dissolved in DCM (10 mL) and reconcentrated by rotary evaporation (3x), after which the
remaining residue was dried under high vacuum. The vacuum dried residue was then dissolved in
1:1 water/MeCN (15 mL) and DIPEA (0.375 mL, 2.15 mmol). Fmoc-OSu (0.252 g, 0.747 mmol)
was then added and allowed to react for 24 hours before the addition of 10 mL of 1 M HCl, which
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formed a precipitate. The reaction was extracted into DCM (3x, 30 mL), washed with sat. NaCl
(1x, 30 mL) and dried over MgSO4 before being concentrated under rotary evaporation. The
residue was solubilized in 3:1 EtOAc/n-hexane and subjected to flash chromatography using 3:1
EtOAc/n-hexane to purify Fmoc-ketomethylene (4) (0.2 g, 73% yield). 1H NMR (500 MHz,
CDCl3) δ 7.78 (d, J = 7.5 Hz, 2H), 7.61 (dd, J = 7.6, 3.6 Hz, 2H), 7.45-7.40 (m, 2H), 7.34 (td, J =
7.5, 1.2 Hz, 2H), 5.53 (d, J = 7.1 Hz, 1H), 4.43 (m, 3H), 4.24 (t, J = 6.8 Hz, 1H), 2.86 (m, 2H),
2.72 (m, 2H), 1.41 (d, J = 7.2 Hz, 3H). LC-ESI-MS: calculated exact mass 368.14 Da, observed
368.13 Da.

6.5 Peptide Synthesis & Analysis
General procedure for solid-phase peptide synthesis. All chemicals were obtained from
commercial sources and were used without further purification. All peptides were synthesized in
glass or plastic synthesis vessels. Peptides were synthesized on a 0.1 mmol scale using Rink amide
MBHA resin. Deprotection was achieved by washing with 20% piperidine/NMP (10 mL, 2x, 20
min) and was followed by washing with NMP (10 mL, 3x, 10 min). To the deprotected resin, a
mixture containing an Fmoc protected amino acid (0.3 mmol), HBTU (0.3 mmol) and DIPEA
solvated in NMP was added, which was left to incubate for 1-24 hrs at room temperature with
shaking. Unreacted coupling components were removed, and the resin washed with NMP (10 mL,
3x, 10 min) before repetition of this process to couple all amino acids. Where appropriate, acetyl
capping of the N-terminus was achieved by combining acetic anhydride (0.3 mmol), DIPEA (0.5
mmol), and NMP (10 mL), which was added to the resin to couple for 2 hrs. Each peptide generated
as a substrate for SML reactions contained the 2-aminobenzoyl (Abz) and 2,4-dinitrophenyl (Dnp)
fluorphore-quencher pair to simplify analysis by UVVis spectroscopy, where Dnp was conjugated
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to the ε-amine of a lysine side chain [Fmoc-K(Dnp)-OH]. After completion of the peptide, the
resin was washed with DCM (10 mL, 3x, 10 min) and incubated with cleavage solution (9.5 mL
TFA, 0.25 mL H2O, 0.25 mL TIPS) for 30 min (5 mL, 2x). The cleaved peptide was collected and
concentrated via rotary evaporation before being precipitated into dry ice-cooled diethyl ether. The
precipitate was centrifuged at 4000xg for 5 min and the ether discarded to afford a peptide pellet,
which was dried under vacuum for 24 hrs. Peptides were solubilized using a mixture of water and
acetonitrile that was variable based on the amino acid composition. Purification from this state was
achieved by RP-HPLC with Method A and the molecular weight of the peptides verified via LCESI-MS with Method B. Peptides were lyophilized and resolubilized in 1:1 water/DMSO or
DMSO to produce stock solutions for use in reactions, which were further analyzed for purity by
RP-HPLC analysis using Method B. For peptides containing the Dnp chromphore, concentrations
were estimated by UV/Vis spectroscopy on a NanodropTM ND-1000 spectrophotometer (Thermo
80 Scientific) at 365 nm using the molar extinction coefficient 17,300 M-1 cm-1 for the Dnp
chromophore.

Activation of Bz-GLPACGG-NH2 (5). After RP-HPLC purification with Method A and subsequent
lyophilization, 5 was combined with 2,2’-dipyridyldisulfide (2x) and solvated in NMP.
Purification of the activated product (6) from reaction mixture was achieved by RP-HPLC with
Method A, and the molecular weight was verified using LC-ESI-MS with Method B. Purified 6
was lyophilized and subsequently resolubilized in 1:10 water/DMSO. An aliquot (1 µL) of 6 was
diluted (100x) in 100 mM DTT and incubated at room temperature for 15-30 minutes. The
concentration was estimated by UV/Vis spectroscopy on a NanodropTM ND-1000
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spectrophotometer (Thermo 80 Scientific) at 343 nm using the molar extinction coefficient 8,080
M-1 cm-1 for the excised 2-mercaptopyridine chromophore.

HPLC purification and analysis was performed using a Dionex Ultimate 3000 HPLC
system. Semi-preparative separations for the purification of peptides were performed with a
Phenomenex Luna 5 µm 100 Å C18 column (10 x 250 mm) fitted with a Phenomenex
SecurityGuard SemiPrep Guard cartridge (10 mm ID). Purification separations were carried out
with the following method: (Method A): MeCN (0.1% formic acid) / 95% H2O, 5% MeCN (0.1%
formic acid) mobile phase. Flow rate = 4.0 mL/min. Gradient = 20% MeCN (0.0-2.0 min), 20%
MeCN to 90% MeCN (2.0-15.0 min), hold 90% MeCN (15.0-17.0 min), 90% MeCN to 10%
MeCN (17.0-17.01 min), re-equilibrate to 10% MeCN (17.01-19.0 min).

Analytical assessments of peptide purity by UV/Vis, following purification with Method A, were
performed with a Phenomenex Kinetex 2.6 µm, 100 Å C18 column (2.1 x 100 mm) with the
method (Method B): MeCN (0.1% formic acid) / 95% H2O, 5% MeCN (0.1% formic acid) mobile
phase. Flow rate = 0.3 mL/min. Gradient = 10% MeCN (0.0-0.5 min), 10% MeCN to 90% MeCN
(0.5-5.0 min), hold 90% MeCN (5.0-7.0 min), 90% MeCN to 10% MeCN (7.0-7.1 min),
reequilibrate to 10% MeCN (7.1-10.0 min).

LC-ESI-MS was performed with a Dionex Ultimate 3000 HPLC system connected inline to an
expressionL high performance compact mass spectrometer (Advion, Inc.). Analytical separations
for UV/Vis and mass spectrometry analysis were performed with a Phenomenex Kinetex 2.6 µm,
100 Å C18 column (2.1 x 100 mm) with Method B.

64

6.6 Analysis of Enzyme Transpeptidation Activity
Reactions were prepared by combining all components shown in Table 5. except enzyme, which
was added to initiate the reaction. Conversion was analyzed by UV/Vis of analytical RP-HPLC
using a Dionex Ultimate 3000 HPLC system (Thermo Scientific) with a Phenomenex Kinetex 2.6
µm, 100 Å C18 column (2.1 x 100 mm) with Method B.
Table 5. Reaction conditions for SML. Water was added to 50 µL total reaction volume unless
otherwise stated.
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